Belite Bio (NASDAQ:BLTE), Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare metabolic and liver disorders. The company’s research platform centers on small-molecule and peptide-based candidates designed to address underlying mechanisms of disease in areas such as nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC) and other orphan indications. Belite Bio’s lead asset is currently in Phase 2 clinical trials, with additional preclinical programs advancing through its proprietary metabolic disease pipeline.
In addition to its internally discovered compounds, Belite Bio collaborates with academic institutions and contract research organizations to optimize formulation, preclinical toxicology and clinical study design. The company has established alliances to leverage complementary expertise in drug delivery and medicinal chemistry, with the goal of accelerating IND-enabling studies and broadening its therapeutic scope. Belite Bio’s pipeline includes multiple candidates at various stages, reflecting a commitment to both first-in-class and best-in-class approaches.
Headquartered in Menlo Park, California, Belite Bio serves patients and research partners across North America, Europe and Asia. The company maintains its own in-house laboratory and works closely with global contract manufacturing organizations to ensure scalable production of its clinical and commercial drug candidates. Through these networks, Belite Bio aims to facilitate international clinical trials and to establish a presence in key markets for rare disease treatment.
Founded in 2008, Belite Bio completed its initial public offering via reverse merger in 2019 and trades on the NASDAQ under the symbol BLTE. The leadership team is led by Chairman and Chief Executive Officer John Xu, Ph.D., who brings extensive experience in biopharmaceutical R&D and strategic partnerships. The executive management group also includes Chief Scientific Officer Richard Wang, Ph.D., and Chief Medical Officer Susan Chen, M.D., each of whom contributes deep expertise in drug discovery and clinical development.
